Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Plant communications
2026
|
| Subjects: | |
| Online Access: | https://pubmed.ncbi.nlm.nih.gov/41858113/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Engineering Salvia miltiorrhiza hairy roots as a scalable platform for high-yield production of paclitaxel and ginsenoside precursors. Lin, Junjie Li, Wei Liu, Yang Yang, Furui Liang, Liang Zeng, Youran Li, Yihong Xue, Zheyong French, Christopher E Guo, Juan Cui, Beimi Liang, Zongsuo Yang, Dongfeng Plant Roots Paclitaxel Salvia miltiorrhiza Ginsenosides Diterpenes Panax notoginseng Metabolic Engineering Taxus Sapogenins Alkenes Plants, Genetically Modified Isomerases Plant-derived natural products offer a rich source of therapeutic agents. However, sustainable and high-yield production remains a grand challenge. We engineered Salvia miltiorrhiza hairy roots to produce taxadiene, a key precursor for the anticancer drug paclitaxel, and protopanaxadiol, a precursor for ginsenosides. The heterologous expression of two key biosynthetic genes, taxadiene synthase from Taxus wallichiana and protopanaxadiol synthase from Panax notoginseng, enabled the production of taxadiene and protopanaxadiol, respectively. Our strategy combined multiple approaches to enhance terpenoid production, including genome editing to redirect metabolic flux by eliminating a competing GGPP sink (via SmCPS1 disruption), transcriptional reprogramming through SmWRKY61 overexpression to enhance terpenoid precursor pathways (MVA/MEP), and optimization of cultivation conditions. This holistic approach yielded 65.17 ± 5.25 mg/kg fresh weight (FW) taxadiene in batch cultures, and the protopanaxadiol yield reached 50.04 ± 2.94 mg/kg dry weight (DW) without optimization. These results highlight the potential of this platform for industrial-scale production. Our findings demonstrate that S. miltiorrhiza hairy roots can serve as a robust and scalable platform to produce valuable plant-derived compounds. This work paves the way for future metabolic engineering efforts to achieve cost-effective and sustainable production of high-value natural products using medicinal plant systems, addressing critical supply bottlenecks for pharmaceutical compounds.